Dxb asx

Dimerix Limited. Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs.

This data is anonymous - we do not track your personal information without your consent. DXB is an early stage biotech research company that is developing an anti-inflammatory drug to treat respiratory and kidney diseases, with potential applications to treat COVID. Due to the pandemic, biotech and life sciences have been at the forefront of global decision making for investors, governments and ordinary consumers. What was once an industry that was considered slow and niche is now rapidly evolving with innovation and technology. We are following the lead of biotech experts at the Merchant Group, DXB is the first investment in their new early stage biotech fund and they have an excellent track record in the sector. This disease has 'orphan drug status', which means that DXB is eligible for accelerated approvals by drug regulators.

Dxb asx

Financial Times Close. Search the FT Search. Show more World link World. Show more US link US. Show more Companies link Companies. Show more Tech link Tech. Show more Markets link Markets. Show more Opinion link Opinion. Show more Personal Finance link Personal Finance. Actions Add to watchlist Add to portfolio Add an alert.

She has broad knowledge of small molecule drug design, optimisation and early clinical development, with expertise which encompasses multiple therapeutic dxb asx.

Dimerix develops and commercialises patient preferred pharmaceutical products for global markets using innovative receptor technology to identify and develop drugs in areas with an unmet need. Nina has over twenty five years of experience in the pharmaceutical industry, with leadership roles in investor relations, business development, and prosecution of intellectual property matters, as well as leading and managing the strategic, scientific and operational aspects of product development. Nina holds a Ph. Sonia is currently Executive Manager at AC Immune, a Nasdaq listed company, and has previously worked within Swiss Stock Exchange listed companies Hoffman la Roche and Addex Therapeutics, where she has held leadership and executive positions across various disciplines in drug discovery, pre-clinical development and translational science and has interacted with regulatory authorities, investors and public funding institutions. She has broad knowledge of small molecule drug design, optimisation and early clinical development, with expertise which encompasses multiple therapeutic areas. Sonia is co-author of more than 50 scientific papers and several patents.

Market data is provided and copyrighted by Thomson Reuters and Morningstar. Click for restrictions. All rights reserved. ASX shareholders. Our Board. Corporate governance.

Dxb asx

Financial Times Close. Search the FT Search. Show more World link World. Show more US link US. Show more Companies link Companies. Show more Tech link Tech. Show more Markets link Markets. Show more Opinion link Opinion. Show more Personal Finance link Personal Finance. Actions Add to watchlist Add to portfolio Add an alert.

Entry level computer technician jobs

See more updates Recent updates. Price AUD 0. Sonia Poli, Non-Executive Director Sonia is currently Executive Manager at AC Immune, a Nasdaq listed company, and has previously worked within Swiss Stock Exchange listed companies Hoffman la Roche and Addex Therapeutics, where she has held leadership and executive positions across various disciplines in drug discovery, pre-clinical development and translational science and has interacted with regulatory authorities, investors and public funding institutions. Dimerix develops and commercialises patient preferred pharmaceutical products for global markets using innovative receptor technology to identify and develop drugs in areas with an unmet need. No thanks. This data is anonymous - we do not track your personal information without your consent. The markets often go quiet before Christmas and during the summer break, with volumes drying up. You must accept the terms and conditions. Please contact Member Services on support investsmart. Milestones Results Publsihed. All content on FT. Please select a quantity for at least one ticket. What do we expect DXB to deliver? Aug 8, Next Investors.

See all ideas. See all brokers.

Clearing and settlement services. What emails do members receive? How share prices can still go up in a bear market Oct 7, Weekender. Please enter your password to proceed. ASX shareholders. Financial Health. Here we are, the final two weeks of June tax-loss selling. Lunch Update. Already a member? Assay labs, brokers and other businesses will soon close their doors before opening again for the new year. Intelligent Investor Membership. Nina has over twenty five years of experience in the pharmaceutical industry, with leadership roles in investor relations, business development, and prosecution of intellectual property matters, as well as leading and managing the strategic, scientific and operational aspects of product development.